Innovating Novel Payload, Dual Payload & Bispecific ADCs to Drive Platform Differentiation that Combats Resistance & Accelerates more ADCs to First & Best-in Class Drugs
The need to move away from biosimilars and innovate novel technologies, has taken the ADC field in South Korea by storm. With novel payloads, dual payloads, and bispecific ADCs taking the center stage, Korean developers are now focused on overcoming Topo 1 ADC challenges to first-in-class ADCs and maximizing success to improve their partnership opportunities with big pharma.
With this in mind, the 5th World ADC Summit South Korea (previously World ADC Asia) is returning to provide you with the most comprehensive platform for South Korea’s rapidly growing ADC community.
Join the likes of Daiichi Sankyo, Astellas, Gilead, AbbVie, Kanaph Therapeutics, OBI Pharma, Aimed Bio, Huadong Medicine, and more, for end-to-end insights on the evolving ADC landscape, novel technologies, dual payloads, and bispecific ADCs to further your ADC development.
Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on targeted protein degradation (TPDs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
Attending Companies Include
참석 기업에는 다음이 포함됩니다